Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Income Before Tax

Profit after all operating and non-operating items but before income tax.

Alector, Inc.NASDAQ: ALEC

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$22.93M, compared with -$40.47M a year earlier. Trailing-twelve-month income before tax was -$125.22M.

Context

  • Income before tax amounted to 678.4% of revenue in FY2025, up 560.1 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$22.93M or moves back toward the trailing-twelve-month quarterly average of -$31.31M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.93M+38.2% QoQ
Last fiscal yearDec 2025
-$142.76M-20.0% YoY
LTMMar 2026
-$125.22M-1.5% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.3%——
1 year-20.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(142.76M) USD
Year-over-year change
-20.0%

Income Before Tax vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.5% is the 5th highest of 9, against a peer median of -7.4%.
  • Income before tax amounts to 679.9% of revenue for ALEC, versus a peer median of 1474.6%.
ALEC Competitors
Income Before Tax for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
PEPGPepGen Inc.LTM Mar 2026-$77.15M USD+24.9%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
NKTXNkarta, Inc.LTM Mar 2026-$99.93M USD+10.2%——
IRDOpus Genetics, Inc.LTM Mar 2026-$106.93M USD-82.4%—892.4%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$113.28M USD+2.6%——
ALECAlector, Inc.LTM Mar 2026-$125.22M USD-1.5%—679.9%
FATEFate Therapeutics, Inc.LTM Mar 2026-$129.91M USD+26.1%—2056.8%
VORVor Biopharma Inc.LTM Mar 2026-$883.08M USD-644.6%——
Peer median (excluding ALEC) —-7.4%—1474.6%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.